Yttrium-90 radioembolization for unresectable hepatic metastases of breast cancer: A systematic review

Table 2 Tumour response to radio-embolization and survival data as reported in the studies included

Ref.	Evaluable patients	Assessment criteria	Follow up (mo)	Tumour response rate (%)	Cases of CR/PR/SD/PD	Overall survival (mo)
Bangash et al[16], 2007	23	WHO	N/A	21/23 (91%)	CR = 9 (39%); PR = 12 (52%); SD = 2 (9%); PD = 0	N/A
Coldwell et al[17], 2007	36	WHO	14	34/36 (94.4%)	CR = 0; PR = 17 (47.2%); SD = 17 (47%); PD=2 (6%)	> 14 for those with CR/PR, 3.6 for those with SD/PD
Stuart et al[18], 2008	7	N/A	N/A	N/A	N/A	20.91
Jakobs et al[19], 2008	23	RECIST	15.7	22/23 (97.2%)	CR = 0; PR = 14 (61%); SD = 8 (35%); PD = 1 (4%)	9.6
Cianni et al[20], 2010	32	RECIST	N/A	32/32 (100%)	CR = 14 (44%); PR = 11 (34%); SD = 7 (22%); PD = 0	N/A
Haug et al[21], 2012	43	RECIST	6	38/43 (88%)	CR = 0; PR = 11 (26%); SD = 27 (62%); PD = 5 (12%)	10.8
Saxena et al[22], 2014	38	RECIST	11.21	27/38 (71%)	CR = 2 (5%); PR = 10 (26%); SD = 15 (39%); PD = 11 (29%)	13.6
Gordon et al[23], 2014	25	RECIST	N/A	21/25 (84%)	CR = 3 (12%); PR/SD = 18 (72%); PD = 4 (16%)	6.61
Bagni et al[24], 2015	17	RECIST	N/A	17/17 (100%)	CR = 2 (12%); PR = 15 (88%); SD = 0; PD = 0	13.5
Fendler et al[25], 2016	56	N/A	N/A	29/56 (52%)	N/A	81
Pieper et al[26], 2016	38	RECIST	N/A	27/38 (71%)	CR = 0; PR = 11 (29%); SD = 16 (42%); PD = 11 (29%)	6
Chang et al[27], 2018	29	mRECIST	N/A	14/29 (48%)	CR = 0; PR = 12 (40%); SD = 2 (0.6%); PD = 15 (50%)	12.9

¹Median value as reported in the original study. N/A: Not available; WHO: World Health Organization; RECIST: Response Evaluation Criteria in Solid Tumours; mRECIST: Modified Response Evaluation Criteria in Solid Tumours; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.